生血丸治疗非小细胞肺癌脾肾阳虚证化疗所致血象下降的临床疗效观察

Clinical efficacy observation of Shengxue Pills in treating hematology decline caused by chemotherapy in nonsmall-cell lung cancer

目的:探讨生血丸用于治疗非小细胞肺癌脾肾阳虚证化疗所致血象下降的临床疗效。方法:将118例非小细胞肺癌化疗患者随机分为两组,治疗组62例采用生血丸联合化疗治疗,对照组56例单纯化疗,评价两组患者化疗后第7、14、21、28、35、42天的血象变化情况。结果:治疗组化疗后血象下降的控制率均优于对照组,具有显著性差异(P<0.05);而且在生活质量改善,中医证候改善等方面治疗组也显著优于对照组(P<0.05)。结论:生血丸预防非小细胞肺癌化疗所致血色素下降,白细胞下降有一定疗效,安全可靠。

Objective：Exploring the clinical curative effects of Shengxue Pills in treating hematology decline caused by chemotherapy in nonsmall-cell lung cancer （NSCLC）. Methods： 118 patients with NSCLC were randomly divided into treatment group and control group. The treatment group of 62 cases was given combination therapy Shengxue Pills and chemotherapy, and the control group of 56 cases was given chemotherapy alone. The changes of hematology were evaluated in the seventh day, fourteenth day, twenty first day, and twenty eighth day of chemotherapy. Results：The total effective rate of the decrease of hematology of HGB, WBC, PLT in the treatment group was significantly lower than that of the control group （P〈0.05）. And the improvement of life quality and symptoms, the treatment group was significantly better than that of the control group （P〈0.05）. Conclusion：The clinical efficacy of Shengxue Pills in prevention of hematology decline caused by chemotherapy in NSCLC is accurate, safe and reliable.